Leerink Partners Begins Coverage on PureTech Health (NASDAQ:PRTC)

Leerink Partners started coverage on shares of PureTech Health (NASDAQ:PRTC) in a research report sent to investors on Monday, MarketBeat.com reports. The firm issued an outperform rating and a $45.00 price target on the stock.

PureTech Health Trading Up 0.5 %

NASDAQ:PRTC opened at $19.89 on Monday. PureTech Health has a 12 month low of $17.08 and a 12 month high of $34.00. The firm has a fifty day simple moving average of $22.26 and a 200-day simple moving average of $25.68.

Institutional Investors Weigh In On PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. AWM Investment Company Inc. bought a new stake in shares of PureTech Health plc (NASDAQ:PRTC) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,900 shares of the company’s stock, valued at approximately $197,000. Institutional investors own 0.04% of the company’s stock.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.